OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.99 EUR 3.28% Market Closed
Market Cap: 131.4m EUR

OSE Immunotherapeutics SA
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OSE Immunotherapeutics SA
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Long-Term Debt
€38.3m
CAGR 3-Years
3%
CAGR 5-Years
29%
CAGR 10-Years
46%
Valneva SE
PAR:VLA
Long-Term Debt
€193m
CAGR 3-Years
23%
CAGR 5-Years
19%
CAGR 10-Years
11%
G
Genfit SA
PAR:GNFT
Long-Term Debt
€59.8m
CAGR 3-Years
-6%
CAGR 5-Years
-19%
CAGR 10-Years
28%
Inventiva SA
PAR:IVA
Long-Term Debt
€48.5m
CAGR 3-Years
77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Long-Term Debt
$6.8m
CAGR 3-Years
-14%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Long-Term Debt
€78.7m
CAGR 3-Years
84%
CAGR 5-Years
43%
CAGR 10-Years
21%

OSE Immunotherapeutics SA
Glance View

Market Cap
130.8m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
3.74 EUR
Overvaluation 38%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Long-Term Debt?
Long-Term Debt
38.3m EUR

Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Long-Term Debt amounts to 38.3m EUR.

What is OSE Immunotherapeutics SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
46%

Over the last year, the Long-Term Debt growth was -1%. The average annual Long-Term Debt growth rates for OSE Immunotherapeutics SA have been 3% over the past three years , 29% over the past five years , and 46% over the past ten years .

Back to Top